Get the Stockscreener App
15.04
0.99%
-0.15
Maze Therapeutics Inc stock is traded at $15.04, with a volume of 354.91K.
It is down -0.99% in the last 24 hours and down -1.38% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$15.19
Open:
$15.3
24h Volume:
354.91K
Relative Volume:
1.91
Market Cap:
$659.52M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.40%
1M Performance:
-1.38%
6M Performance:
+27.03%
1Y Performance:
+0.00%
1-Day Range:
$14.16
$15.68
1-Week Range:
$13.89
$16.40
52-Week Range:
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
15.04 | 671.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
What is Maze Therapeutics Inc.’s book value per share2025 Bull vs Bear & Stepwise Entry and Exit Trade Signals - khodrobank.com
Entry Recap: Is Maze Therapeutics Inc. a cyclical or defensive stockMarket Trend Report & Verified Momentum Watchlists - khodrobank.com
Should you wait for a breakout in Maze Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Maze Therapeutics Inc. stock chart pattern explainedPortfolio Profit Report & Daily Chart Pattern Signal Reports - Newser
Custom strategy builders for tracking Maze Therapeutics Inc.M&A Rumor & Consistent Growth Stock Picks - Newser
Sentiment analysis tools applied to Maze Therapeutics Inc.Portfolio Value Report & Intraday High Probability Setup Alerts - Newser
Using data models to predict Maze Therapeutics Inc. stock movementStop Loss & Precise Swing Trade Alerts - Newser
Is Maze Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Review & Verified Momentum Watchlists - Newser
Understanding Maze Therapeutics Inc.’s price movementOptions Play & Daily Profit Focused Stock Screening - Newser
What MACD and RSI say about Maze Therapeutics Inc.2025 Valuation Update & Real-Time Stock Movement Alerts - Newser
What indicators show strength in Maze Therapeutics Inc.July 2025 Setups & AI Enhanced Trading Signals - Newser
Statistical indicators supporting Maze Therapeutics Inc.’s strengthBreakout Watch & Weekly High Return Stock Forecasts - Newser
Maze Therapeutics Inc. stock volume spike explained2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - Newser
Can Maze Therapeutics Inc. grow without dilutionDividend Hike & Verified Technical Signals - khodrobank.com
Risk vs reward if holding onto Maze Therapeutics Inc.July 2025 Opening Moves & Safe Entry Point Alerts - Newser
Multi asset correlation models including Maze Therapeutics Inc.Risk Management & Weekly Chart Analysis and Guides - Newser
Maze Therapeutics’ Claims For Unapproved Kidney Disease Drug Face Regulatory Scrutiny - insights.citeline.com
Should value investors consider Maze Therapeutics Inc.July 2025 Levels & Growth Focused Stock Reports - khodrobank.com
Is it too late to sell Maze Therapeutics Inc.Market Growth Report & Breakout Confirmation Trade Signals - Newser
Visual analytics tools that track Maze Therapeutics Inc. performanceProduct Launch & Free Reliable Trade Execution Plans - Newser
Maze Therapeutics appoints Misbah Tahir as chief financial officer - Investing.com India
Maze Therapeutics initiated with a Buy at BTIG - TipRanks
BTIG initiates coverage on Maze Therapeutics with a Buy rating and PT of $30. - AInvest
Maze Therapeutics appoints Tahir as Chief Financial Officer - TipRanks
Maze Therapeutics Appoints Misbah Tahir as CFO - TipRanks
Maze Therapeutics Appoints Misbah Tahir as New CFO - AInvest
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewswire
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewswire Inc.
BTIG Initiates Maze Therapeutics at Buy With $30 Price Target - MarketScreener
Is Maze Therapeutics Inc. stock showing strong momentum2025 Institutional Moves & Technical Pattern Recognition Alerts - khodrobank.com
How to monitor Maze Therapeutics Inc. with trend dashboardsWeekly Trend Recap & Real-Time Buy Signal Alerts - Newser
Can Maze Therapeutics Inc. outperform in the next rallyLayoff News & Community Verified Trade Signals - khodrobank.com
Will Maze Therapeutics Inc. stock recover after earningsWeekly Investment Recap & AI Driven Stock Movement Reports - khodrobank.com
Maze Therapeutics Inc. Breakout Confirmed by Volume Metrics getLinesFromResByArray error: size == 0 - 강소기업뉴스
Institutional scanner results for Maze Therapeutics Inc.2025 Top Gainers & Technical Confirmation Trade Alerts - Newser
Historical volatility pattern of Maze Therapeutics Inc. visualizedTrade Signal Summary & Real-Time Volume Triggers - Newser
Can trapped investors hope for a rebound in Maze Therapeutics Inc.2025 Earnings Impact & Daily Volume Surge Trade Alerts - Newser
Will Maze Therapeutics Inc. benefit from seasonality getLinesFromResByArray error: size == 0 - sisain.net
Maze Therapeutics Inc. Approaches Psychological Resistance Level getLinesFromResByArray error: size == 0 - newsyoung.net
Is it time to cut losses on Maze Therapeutics Inc.2025 Analyst Calls & AI Driven Stock Reports - Newser
When is the best time to exit Maze Therapeutics Inc.Gold Moves & AI Forecast for Swing Trade Picks - Newser
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):